Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30819391 | 0.82 | PRSS1 (0.49) | L3MBTL1 | |
| SCHEMBL11614989 | 0.77 | PRKCI (0.49) | PRKCITDP1ALDH1A1GAA | |
| SCHEMBL11615543 | 0.68 | PRKCI (0.38) | PRKCIALDH1A1 | |
| SCHEMBL19086455 | 0.68 | GAA (0.48) | CA1CA2ALDH1A1GAAL3MBTL1 | |
| SCHEMBL15880501 | 0.67 | PRKCI (0.62) | PRKCI | |
| SCHEMBL25099306 | 0.65 | HASPIN (0.43) | CA1CA2TDP1ALDH1A1 | |
| SCHEMBL27627388 | 0.65 | PRKCI (0.63) | PRKCIALDH1A1 | |
| SCHEMBL25139429 | 0.65 | HSD17B10 (0.49) | ALDH1A1GAAL3MBTL1 | |
| SCHEMBL28292631 | 0.64 | PRKCI (0.48) | PRKCIGAA | |
| SCHEMBL12252467 | 0.64 | GABRP (0.58) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132480-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC. | 2024-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132480-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | DLD, GCDH, DLAT | PRKCI 3276/4885CA1 3932/4885CA2 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.